BR9913026A - Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano - Google Patents
Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humanoInfo
- Publication number
- BR9913026A BR9913026A BR9913026A BR9913026A BR9913026A BR 9913026 A BR9913026 A BR 9913026A BR 9913026 A BR9913026 A BR 9913026A BR 9913026 A BR9913026 A BR 9913026A BR 9913026 A BR9913026 A BR 9913026A
- Authority
- BR
- Brazil
- Prior art keywords
- vlps
- papillomavirus
- particles
- preparing
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000002245 particle Substances 0.000 title abstract 3
- 241000701806 Human papillomavirus Species 0.000 title abstract 2
- 241001631646 Papillomaviridae Species 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- -1 phosphate anion Chemical class 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"PROCESSO DE PURIFICAçãO DE PARTìCULAS SEMELHANTES A VìRUS (VLPS) DE PAPILOMAVìRUS RECOMBINANTE, E, PROCESSO DE PREPARAçãO DE UM PRODUTO DE VLP DE PAPILOMAVìRUS HUMANO PURIFICADO ADEQUADO PARA USO EM UMA VACINA PARA HUMANO". Um processo para purificação de partículas semelhantes a vírus (VLPs) de papilomavírus inclui a etapa de passar uma solução contendo VLP parcialmente purificada através de uma coluna cromatográfica de hidróxi-apatita. As VLPs são então eluídas utilizando um tampão contendo ânion fosfato. As vantagens deste processo incluem a recuperação de um elevado rendimento de VLPs intactas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9656898P | 1998-08-14 | 1998-08-14 | |
PCT/US1999/017930 WO2000009671A1 (en) | 1998-08-14 | 1999-08-10 | Process for purifying human papillomavirus virus-like particles |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9913026A true BR9913026A (pt) | 2001-09-25 |
Family
ID=22257989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9913026A BR9913026A (pt) | 1998-08-14 | 1999-08-10 | Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano |
Country Status (24)
Country | Link |
---|---|
US (1) | US6602697B1 (pt) |
EP (1) | EP1105466B1 (pt) |
JP (1) | JP4440471B2 (pt) |
KR (1) | KR20010072470A (pt) |
CN (1) | CN1354787A (pt) |
AT (1) | ATE324436T1 (pt) |
AU (1) | AU760633B2 (pt) |
BR (1) | BR9913026A (pt) |
CA (1) | CA2339034C (pt) |
CY (1) | CY1105084T1 (pt) |
CZ (1) | CZ2001570A3 (pt) |
DE (1) | DE69931053T2 (pt) |
DK (1) | DK1105466T3 (pt) |
EA (1) | EA200100236A1 (pt) |
ES (1) | ES2262333T3 (pt) |
HR (1) | HRP20010113A2 (pt) |
HU (1) | HUP0103091A3 (pt) |
IL (1) | IL141130A0 (pt) |
NZ (1) | NZ509610A (pt) |
PL (1) | PL347472A1 (pt) |
PT (1) | PT1105466E (pt) |
SI (1) | SI1105466T1 (pt) |
SK (1) | SK2232001A3 (pt) |
WO (1) | WO2000009671A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2266604A3 (en) * | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
JP2000262280A (ja) * | 1999-03-18 | 2000-09-26 | Asahi Optical Co Ltd | ウィルスまたはウィルス性抗原の精製方法およびワクチンの製造方法 |
US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
US7479222B2 (en) * | 2004-02-05 | 2009-01-20 | Millipore Corporation | Porous adsorptive or chromatographic media |
CA2560487C (en) * | 2004-03-24 | 2013-01-29 | Merck & Co., Inc. | Optimized expression of hpv 52 l1 in yeast |
AU2005280896B2 (en) | 2004-09-10 | 2010-08-05 | Asahi Glass Company, Limited | Vaccine for oral administration |
EP1736538A1 (en) * | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
US20100288029A1 (en) * | 2006-08-30 | 2010-11-18 | Ge Healthcar Bio-Sciences Corp. | System and method for characterizing membranes and membrane filtration devices |
EP2601969B1 (en) | 2006-09-29 | 2016-03-30 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
ATE496935T1 (de) * | 2007-02-22 | 2011-02-15 | Baxter Int | Verfahren zur aufreinigung hydrophober proteine |
HUE028605T2 (en) | 2007-03-14 | 2016-12-28 | Takeda Vaccines Inc | Cleaning virus-like particles |
WO2008134935A1 (fr) | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Protéines 18 l1 de type papillomavirus humain tronqué |
DK2154147T3 (en) | 2007-04-29 | 2015-12-07 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | Truncated L1 protein of human papillomavirus 16 |
WO2008145021A1 (en) * | 2007-05-29 | 2008-12-04 | Xiamen University | A truncated l1 protein of human papillomavirus 6 |
US9433922B2 (en) | 2007-08-14 | 2016-09-06 | Emd Millipore Corporation | Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same |
US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
JP2010539192A (ja) * | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
EP2011573B1 (en) * | 2007-11-05 | 2010-07-21 | Agilent Technologies, Inc. | Freezing a microfluidic chip |
US20090130738A1 (en) * | 2007-11-19 | 2009-05-21 | Mikhail Kozlov | Media for membrane ion exchange chromatography |
EP3382011A1 (en) | 2008-08-08 | 2018-10-03 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
CA2787009C (en) | 2010-01-15 | 2018-04-03 | Bio-Rad Laboratories, Inc. | Surface neutralization of apatite |
JP2013523175A (ja) | 2010-04-14 | 2013-06-17 | イーエムディー・ミリポア・コーポレーション | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
US8895707B2 (en) | 2010-08-18 | 2014-11-25 | Bio-Rad Laboratories, Inc. | Elution of proteins from hydroxyapatite resins without resin deterioration |
CA2825651C (en) | 2011-02-02 | 2020-03-24 | Bio-Rad Laboratories, Inc. | Apatite surface neutralization with alkali solutions |
PL3299030T3 (pl) | 2011-07-11 | 2022-12-05 | Takeda Vaccines, Inc. | Pozajelitowe preparaty szczepionek przeciw norowirusowi |
MX355352B (es) | 2011-12-01 | 2018-04-17 | Univ Cape Town | Particulas quimericas de vph. |
US9815695B2 (en) | 2012-05-30 | 2017-11-14 | Bio-Rad Laboratories, Inc. | In situ restoration of apatite-based chromatography resins |
JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
JP6479305B2 (ja) * | 2013-07-12 | 2019-03-06 | 株式会社Umnファーマ | ウイルス様粒子の精製方法 |
CN105392569B (zh) | 2014-06-23 | 2019-08-20 | 生物辐射实验室股份有限公司 | 磷灰石预处理 |
US10092857B2 (en) | 2014-06-23 | 2018-10-09 | Bio-Rad Laboratories, Inc. | Apatite in-situ restoration |
CN105907729B (zh) * | 2015-05-05 | 2019-08-16 | 广东东阳光药业有限公司 | 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法 |
CN108524929B (zh) * | 2017-03-06 | 2019-05-07 | 广州瑞贝斯药业有限公司 | 一种狂犬病疫苗的生产方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6078999A (ja) | 1983-10-05 | 1985-05-04 | Chemo Sero Therapeut Res Inst | HBs抗原の精製方法 |
SE9000650L (sv) | 1989-02-28 | 1990-08-29 | Asahi Optical Co Ltd | Separation av celler eller virus |
CA2189882C (en) * | 1994-05-16 | 2005-09-20 | Kathrin U. Jansen | Papillomavirus vaccines |
CA2200582C (en) * | 1994-09-22 | 2007-03-27 | Merck & Co., Inc. | Dna encoding human papillomavirus type 6a |
AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
US6143548A (en) * | 1995-08-30 | 2000-11-07 | Genzyme Corporation | Chromatographic purification of adeno-associated virus (AAV) |
-
1999
- 1999-08-10 SK SK223-2001A patent/SK2232001A3/sk unknown
- 1999-08-10 CA CA 2339034 patent/CA2339034C/en not_active Expired - Lifetime
- 1999-08-10 WO PCT/US1999/017930 patent/WO2000009671A1/en active IP Right Grant
- 1999-08-10 EA EA200100236A patent/EA200100236A1/ru unknown
- 1999-08-10 SI SI9930901T patent/SI1105466T1/sl unknown
- 1999-08-10 DE DE1999631053 patent/DE69931053T2/de not_active Expired - Lifetime
- 1999-08-10 NZ NZ50961099A patent/NZ509610A/xx not_active IP Right Cessation
- 1999-08-10 HU HU0103091A patent/HUP0103091A3/hu unknown
- 1999-08-10 AT AT99940950T patent/ATE324436T1/de active
- 1999-08-10 PL PL34747299A patent/PL347472A1/xx unknown
- 1999-08-10 AU AU54698/99A patent/AU760633B2/en not_active Expired
- 1999-08-10 CZ CZ2001570A patent/CZ2001570A3/cs unknown
- 1999-08-10 JP JP2000565108A patent/JP4440471B2/ja not_active Expired - Lifetime
- 1999-08-10 DK DK99940950T patent/DK1105466T3/da active
- 1999-08-10 US US09/762,662 patent/US6602697B1/en not_active Expired - Lifetime
- 1999-08-10 BR BR9913026A patent/BR9913026A/pt not_active Application Discontinuation
- 1999-08-10 EP EP99940950A patent/EP1105466B1/en not_active Expired - Lifetime
- 1999-08-10 PT PT99940950T patent/PT1105466E/pt unknown
- 1999-08-10 ES ES99940950T patent/ES2262333T3/es not_active Expired - Lifetime
- 1999-08-10 CN CN99811968A patent/CN1354787A/zh active Pending
- 1999-08-10 KR KR1020017001885A patent/KR20010072470A/ko not_active Application Discontinuation
- 1999-08-10 IL IL14113099A patent/IL141130A0/xx unknown
-
2001
- 2001-02-14 HR HR20010113A patent/HRP20010113A2/hr not_active Application Discontinuation
-
2006
- 2006-07-11 CY CY20061100963T patent/CY1105084T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1105466T1 (sl) | 2006-08-31 |
EA200100236A1 (ru) | 2001-08-27 |
PT1105466E (pt) | 2006-07-31 |
ATE324436T1 (de) | 2006-05-15 |
CN1354787A (zh) | 2002-06-19 |
HUP0103091A3 (en) | 2002-03-28 |
EP1105466A4 (en) | 2002-05-15 |
DK1105466T3 (da) | 2006-08-14 |
NZ509610A (en) | 2002-10-25 |
EP1105466A1 (en) | 2001-06-13 |
CA2339034A1 (en) | 2000-02-24 |
WO2000009671A1 (en) | 2000-02-24 |
US6602697B1 (en) | 2003-08-05 |
DE69931053T2 (de) | 2006-11-23 |
AU5469899A (en) | 2000-03-06 |
EP1105466B1 (en) | 2006-04-26 |
ES2262333T3 (es) | 2006-11-16 |
SK2232001A3 (en) | 2001-08-06 |
HUP0103091A2 (hu) | 2001-12-28 |
PL347472A1 (en) | 2002-04-08 |
HRP20010113A2 (en) | 2002-02-28 |
KR20010072470A (ko) | 2001-07-31 |
CA2339034C (en) | 2010-10-12 |
CZ2001570A3 (cs) | 2001-09-12 |
DE69931053D1 (de) | 2006-06-01 |
IL141130A0 (en) | 2002-02-10 |
JP4440471B2 (ja) | 2010-03-24 |
AU760633B2 (en) | 2003-05-22 |
CY1105084T1 (el) | 2009-11-04 |
JP2003520188A (ja) | 2003-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9913026A (pt) | Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano | |
FR11C0022I1 (pt) | ||
NL300324I1 (nl) | Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze | |
DE60029195D1 (de) | Verfahren zur gewinnung von purifizierter virenzuammensetzung | |
DE69535018D1 (de) | Papillomavirus vakzine | |
LU91314I9 (pt) | ||
MY139031A (en) | Vaccine composition comprising virus-like particles of human papillomavirus | |
MX9701183A (es) | Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones. | |
WO2004000220A3 (en) | Methods for purifying viral particles for gene therapy | |
AU6941287A (en) | Vaccines for human respiratory virus | |
EP0816374A3 (en) | A method of preparing a composition containing a high proportion of ganglioside | |
BR0003392A (pt) | Processo para produzir xilitol de alta pureza | |
MXPA03007992A (es) | Composicion farmaceutica de fragmentos f(ab)2 de anticuerpos y un proceso para su preparacion | |
DE59814240D1 (de) | Hyaluronidase enthaltendes Präparat und pharmazeutische Verwendung davon | |
HUP0100132A2 (hu) | A béta-lipotropin és felhasználása | |
TW368505B (en) | A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same | |
AU2001287739A1 (en) | Process for the purification of epi-hne proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |